PropThink: ARIAD Building an Oncology Business Around Discovery, Development, and Commercialization

In an exclusive PropThink interview with ARIAD Pharmaceuticals ARIA, CEO Harvey J. Berger discusses the company's lead product, ponatinib, a potential treatment  for intolerant Chronic Myeloid Leukemia (CML) which was submitted in full to the FDA for regulatory review in late September. Berger explains that CML is an enormous market opportunity - upwards of $5 billion - and that ponatinib has shown promising results as an important treatment option. He discusses timeframes for an ongoing Phase III head-to-head trial of ponatinib against Novartis' NVS Gleevec, one of the primary CML treatments on the market, and says that ponatinib is the first BCR-ABL inhibitor that blocks all mutations and resistances in the protein. That trial, he says, may set the stage for ponatinib to become a therapy for newly-diagnosed patients, and compete with drugs like Gleevec and Tasigna, both from Novartis, and Bristol-Myers Squibb's BMY Sprycel.

The interview also includes discussion of AP26113, ARIAD's early-stage drug for Non Small-Cell Lung Cancer (NSCLC). While existing treatments such as Pfizer's PFE Xalkori ultimately fail at some point during treatment, Berger believes AP26113 will overcome those resistances and shortcomings. The drug's first clinical data was released in September, and Berger discusses the next step in development, a pivotal trial for the treatment. He also mentions the company's ambitious plan for product commercialization and the events that have driven ARIAD to become a $4 billion company.

See Our Interview with ARIAD Pharmaceuticals by Clicking Here

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter or visit us at http://www.propthink.com.